Copertina

Exploratory Analysis of Practical Predictive Indices for the Efficacy of Mogamulizumab in Patients With Aggressive Adult T‐Cell Leukemia‐Lymphoma

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Yutaka Shimazu, Kenta Murotani, Hiroki Kitabayashi, Yukihiro Nishio
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Hematological Oncology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma
di: Meirav Kedmi, et al.
Pubblicazione: (2024)

Baseline Tumor Burden Assessed With AI‐Guided PET/CT Total Metabolic Tumor Volume (TMTV) and LDH Levels Predict Efficacy of CAR‐T in Aggressive B‐Cell Lymphoma
di: Eugenio Galli, et al.
Pubblicazione: (2024)

Routine Monitoring of CAR‐T‐Cells Expansion and Persistence in Patients With Aggressive Large B‐Cell Lymphoma by Flow Cytometry: A Single‐Center Experience
di: Alexandra Zduniak, et al.
Pubblicazione: (2025)

Clinical Outcomes of CD7 CAR‐T Cell Therapy in Relapsed or Refractory T‐Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients
di: Jinyan Xiao, et al.
Pubblicazione: (2025)

CAR T‐Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real‐World Experiences From a Single Center on the Use of Radiotherapy
di: J.T. Jutzi, et al.
Pubblicazione: (2025)

A Multicenter Real‐World Retrospective Study for Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, and Prednisolone for Previously Untreated Patients With CD30‐Positive Adult T‐Cell Leukemia‐Lymphoma
di: Masahito Tokunaga, et al.
Pubblicazione: (2025)

RETRACTION: Burkitt Lymphoma Versus Diffuse Large B‐Cell Lymphoma: A Practical Approach
Pubblicazione: (2026)

CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia
di: Marilisa Galasso, et al.
Pubblicazione: (2024)

Correction to “Defining and Addressing the Current Unmet Medical Needs for the Frontline Treatment of Advanced Stage Aggressive Large B‐Cell Lymphoma: A Perspective From an Ad Hoc Panel of Italian Experts”
Pubblicazione: (2025)

Peripheral T‐Cell Lymphoma: What's Next?
di: Sang Eun Yoon, et al.
Pubblicazione: (2025)

Post‐CAR T‐Cell Therapy Failure Metabolic Parameters Predict Survival and Response in Large B‐Cell Lymphoma
di: Hazim S. Ababneh, et al.
Pubblicazione: (2024)

Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell Lymphoma
di: Juliette Penichoux, et al.
Pubblicazione: (2025)

First Line Therapy in Mantle Cell Lymphoma—The Role of BTKi in the Initial Treatment of Transplant‐Eligible and ‐Ineligible Patients
di: E. Silkenstedt, et al.
Pubblicazione: (2025)

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third‐Line CAR T
di: Inna Y. Gong, et al.
Pubblicazione: (2026)

Comprehensive Analysis of Single‐Cell and Bulk Transcriptomics Identified Regulatory T‐Cell Features as Predictors of Prognosis in Diffuse Large B‐Cell Lymphoma
di: Yaoli Cui, et al.
Pubblicazione: (2025)

Outcome of Adult Lymphoblastic Lymphoma Patients Treated in the Real Life According to the Gimema LAL1913 Protocol: A Campus ALL Multicenter Study
di: M. Delia, et al.
Pubblicazione: (2025)

International Cost‐Effectiveness Analysis of Nivolumab Versus Brentuximab Vedotin for Patients With Advanced‐Stage Classic Hodgkin's Lymphoma
di: Youwen Zhu, et al.
Pubblicazione: (2026)

Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real‐World Data
di: Minna Harmanen, et al.
Pubblicazione: (2025)

Clinical Outcomes in Double‐Exposed Chronic Lymphocytic Leukemia Patients in Italy
di: Francesco Autore, et al.
Pubblicazione: (2026)

Combining Total Metabolic Tumor Volume With Beta‐2‐Microglobulin Levels Predicts Outcomes in High‐Burden Follicular Lymphoma Patients
di: A. Zduniak, et al.
Pubblicazione: (2024)

Genetic and Transcriptomic Profiles Identify Potential Therapeutic Targets of Concurrent Follicular and Diffuse Large B‐Cell Lymphoma and Transformed Follicular Lymphoma
di: Rui Sun, et al.
Pubblicazione: (2026)

The Efficacy and Safety of the Addition of Mitoxantrone Hydrochloride Liposome in Conditioning Regimen for High‐Risk Acute Myeloid Leukemia
di: Xiaoyu Zhang, et al.
Pubblicazione: (2025)

Indolent T‐Cell Lymphoma of the Gastrointestinal Tract Associated With Strongyloides Stercoralis Infection
di: Yue Zhao, et al.
Pubblicazione: (2025)

A Novel Prognostic Score for Disease Progression and Mortality in Patients With Newly Diagnosed Primary Large B‐Cell Lymphoma of Immune‐Privileged Sites
di: Ganggang Wang, et al.
Pubblicazione: (2025)

Advancing Mantle Cell Lymphoma Risk Assessment: Navigating a Moving Target
di: Simone Ferrero, et al.
Pubblicazione: (2025)

Knockdown of VDAC1 Promotes Ferroptosis in Diffuse Large B‐Cell Lymphoma
di: Chuanming Lin, et al.
Pubblicazione: (2025)

Clinicopathological Characteristics of Extranodal Marginal Zone Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT‐Lymphoma) of the Intestine: A Single Center Analysis
di: Oskar Steinbrecher, et al.
Pubblicazione: (2024)

A SWOT‐Consensus for CAR‐T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection
di: Monia Marchetti, et al.
Pubblicazione: (2025)

Molecular Features of Diffuse Large B‐Cell Lymphoma Associated With Primary Treatment Resistance
di: Allison M. Bock, et al.
Pubblicazione: (2024)

Prognostic Value of C‐Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma
di: Akihiko Izumi, et al.
Pubblicazione: (2025)

Efferocytosis and M2 Macrophage Polarization Gene Expression Correlates With Relapsed and Refractory Classical Hodgkin Lymphoma Patients: A Multi‐Omic Analysis
di: Juan Quarroz Braghini, et al.
Pubblicazione: (2025)

MerTK is Ectopically Expressed and Affects the Biological Function in Diffuse Large B‐Cell Lymphoma
di: Yan Li, et al.
Pubblicazione: (2025)

Zanubrutinib in Hairy Cell Leukemia Variant: Clinical Report and Overview of BTK Inhibition in Variant Disease
di: A. Bernardelli, et al.
Pubblicazione: (2026)

Comparative Safety of Ibrutinib Versus Zanubrutinib in Patients With Chronic Lymphocytic Leukemia: A Prospective Cohort Study
di: Fuli Fan, et al.
Pubblicazione: (2025)

Changes in Lean Muscle Mass, Muscle Strength, and Physical Performance Following First‐Line Chemotherapy in Patients With Lymphoma
di: Charlotte Nørregaard Grønset, et al.
Pubblicazione: (2025)

Trends in Incidence and Survival of Patients With Primary Effusion Lymphoma in the United States: A Population Based Cohort Study
di: John L. Vaughn, et al.
Pubblicazione: (2026)

Gene Expression Profiling in Acute Myeloid Leukemia Patient Subgroups With High and Low Sensitivity Toward SYK Inhibitors
di: Marte Karen Brattås, et al.
Pubblicazione: (2025)

Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia
di: Georgio Medawar, et al.
Pubblicazione: (2026)

Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B‐Cell Lymphoma in the Compassionate Use Program in Italy
di: Pier Luigi Zinzani, et al.
Pubblicazione: (2025)

Late Cardiac Toxicity After Anthracyclines and Radiotherapy for Lymphoma—A Regression Analysis of Dose‐Response
di: Lotte Nygård, et al.
Pubblicazione: (2025)